Designing CD4 immunoadhesins for AIDS therapy (2007)
Capon, D. J., Chamow, S. M., Mordenti, J., Marsters, S. A., Gregory, T., Mitsuya, H., ...
A newly-constructed antibody-like molecule containing the gp120-binding domain of the receptor for human immunodeficiency virus blocks HIV-1 infection of T cells and monocytes. Its long plasma...
Biological properties of a CD4 immunoadhesin (2007)
Byrn, R. A., Mordenti, J., Lucas, C., Smith, D., Marsters, S. A., Johnson, J. S., ...
Molecular fusions of CD4, the receptor for human immunodeficiency virus (HIV), with immunoglobulin (termed CD4 immunoadhesins) possess both the gp120-binding and HIV-blocking properties of...
Shearer, W T, Duliege, A M, Kline, M W, Hammill, H, Minkoff, H, Ammann, A J, ...
Recombinant CD4-immunoglobulin G (rCD4-IgG) is a 98-kDa human immunoglobulin-like protein that is produced by fusing the gp120 binding domain of CD4 to the Fc portion of the human IgG1 heavy chain....
Barriere, S L, Ozasa, D C, Mordenti, J
Bactericidal activity in serum produced after administration of 1-g intravenous doses of cefoperazone, cefotaxime, ceftizoxime, and moxalactam was ascertained in six healthy subjects. The assay...
The postdistribution half-lives of 10 cephalosporin and 2 monobactam antibiotics in humans were predicted from data obtained in other mammals. This forecasting was accomplished with the allometric...
Hodges, T L, Kahn, J O, Kaplan, L D, Groopman, J E, Volberding, P A, Amman, A J, ...
The safety and pharmacokinetics of recombinant CD4-immunoglobulin G (rCD4-IgG) were evaluated in a phase 1 study with dose escalation. A total of 16 patients, 6 with AIDS and 10 with AIDS-related...
Effect of dose on pharmacokinetics and serum bactericidal activity of mezlocillin.
Flaherty, J F, Barriere, S L, Mordenti, J, Gambertoglio, J G
Mezlocillin is subject to dose-dependent pharmacokinetics. Previous studies have examined the pharmacokinetic but not the pharmacodynamic aspects of this effect. The pharmacokinetic disposition of...
Shearer, W T, Duliege, A M, Kline, M W, Hammill, H, Minkoff, H, Ammann, A J, ...
Recombinant CD4-immunoglobulin G (rCD4-IgG) is a 98-kDa human immunoglobulin-like protein that is produced by fusing the gp120 binding domain of CD4 to the Fc portion of the human IgG1 heavy chain....
Barriere, S L, Ozasa, D C, Mordenti, J
Bactericidal activity in serum produced after administration of 1-g intravenous doses of cefoperazone, cefotaxime, ceftizoxime, and moxalactam was ascertained in six healthy subjects. The assay...
The postdistribution half-lives of 10 cephalosporin and 2 monobactam antibiotics in humans were predicted from data obtained in other mammals. This forecasting was accomplished with the allometric...
Hodges, T L, Kahn, J O, Kaplan, L D, Groopman, J E, Volberding, P A, Amman, A J, ...
The safety and pharmacokinetics of recombinant CD4-immunoglobulin G (rCD4-IgG) were evaluated in a phase 1 study with dose escalation. A total of 16 patients, 6 with AIDS and 10 with AIDS-related...
Effect of dose on pharmacokinetics and serum bactericidal activity of mezlocillin.
Flaherty, J F, Barriere, S L, Mordenti, J, Gambertoglio, J G
Mezlocillin is subject to dose-dependent pharmacokinetics. Previous studies have examined the pharmacokinetic but not the pharmacodynamic aspects of this effect. The pharmacokinetic disposition of...